EBOS GROUP LIMITED (EBO)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

EBO

EBO - EBOS GROUP LIMITED

FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 2.84
Index: ASX300 | ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$29.27

28 Aug
2025

-0.920

OPEN

$29.99

-3.05%

HIGH

$29.99

283,017

LOW

$28.01

TARGET
$34.873

-1.44 change from previous day

 19.1% upside
Franking for last dividend paid out: 96%
OTHER COMPANIES IN THE SAME SECTOR
ACL . AHX . ALC . BMT . DOC . HLS . IDX . M7T . MDR . MPL . MVF . NHF . PSQ . RHC . SHL .
FNARENA'S MARKET CONSENSUS FORECASTS
EBO: 1
Title FY24
Actual		 FY25
Actual		 FY26
Forecast		 FY27
Forecast
EPS (cps) xxx 109.7 144.9 xxx
DPS (cps) xxx 112.9 114.6 xxx
EPS Growth xxx - 22.4% 32.0% xxx
DPS Growth xxx N/A 1.5% xxx
PE Ratio xxx N/A 20.2 xxx
Dividend Yield xxx N/A 3.9% xxx
Div Pay Ratio(%) xxx 102.9% 79.1% xxx

Dividend yield today if purchased 3 years ago: 3.37%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 3.85

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 29/08 - ex-div 49.71c (franking 49%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx109.7
DPS All xxxxxxxxxxxxxxx112.9
Sales/Revenue xxxxxxxxxxxxxxx12,266.9 M
Book Value Per Share xxxxxxxxxxxxxxx1,348.0
Net Operating Cash Flow xxxxxxxxxxxxxxx418.5 M
Net Profit Margin xxxxxxxxxxxxxxx1.75 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx8.29 %
Return on Invested Capital xxxxxxxxxxxxxxx5.70 %
Return on Assets xxxxxxxxxxxxxxx3.07 %
Return on Equity xxxxxxxxxxxxxxx8.29 %
Return on Total Capital xxxxxxxxxxxxxxx10.08 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx156.3 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx82 M
Long Term Debt xxxxxxxxxxxxxxx1,540 M
Total Debt xxxxxxxxxxxxxxx1,622 M
Goodwill - Gross xxxxxxxxxxxxxxx2,245 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx184 M
Price To Book Value xxxxxxxxxxxxxxx2.64

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx146.0 M
Capex % of Sales xxxxxxxxxxxxxxx1.19 %
Cost of Goods Sold xxxxxxxxxxxxxxx11,346 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx497 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx95 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.4

No. Of Recommendations

5
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

xx/xx/xxxx

2

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

xx/xx/xxxx

1

xxxxxxxxxx

-

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

UBS

28/08/2025

1

Buy

-

-

UBS retains Buy and cuts the 12-month target to NZ$39.50 from NZ$44.50 after a sizeable FY26 earnings reset as well as higher capex.

FY25 underwhelmed (underlying 2H25 EBITDA missed by -5%) and FY26 guidance embeds lower Community Pharmacy gross margins and higher operating costs, partly offset by stronger Institutional Healthcare.

Forecasts are reduced: EPS -20%/-19%/-18% for 2026-28, with FY26 roughly flat on FY25 before a 17% rebound in FY27 on improved PBS wholesaler funding.

UBS argues valuation remains appealing for a diversified, cash-generative business (circa 20x FY27 P/E), though a short-term re-rating catalyst is hard to identify post reset.

FORECAST
UBS forecasts a full year FY26 dividend of 118.00 cents and EPS of 131.00 cents.
UBS forecasts a full year FY27 dividend of 123.00 cents and EPS of 154.00 cents.

Ord Minnett

xx/xx/xxxx

2

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

xx/xx/xxxx

5

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Jarden

24/07/2025

2

Overweight

-

-

Jarden reiterates its Overweight rating on Ebos Group, noting the strong structural growth in PBS expenditure as a key underpinning of the company's forward earnings.

The broker highlights an around 9% compound annual growth rate (CAGR) in PBS spend over the past three years.

This growth rate is supported by drug innovation and a favourable regulatory backdrop under the 8th Community Pharmacy Agreement and First Pharmaceutical Wholesaler Agreement, explain the analysts.

The group is expected to benefit from consistent high single-digit growth in S-85 (Community Pharmacy) and circa 7% growth in S-100 (Hospital), with additional upside from GLP-1 penetration if PBS expands coverage.

The broker flags potential EPS upgrades by the market pending policy clarity and lifts its FY27 and FY28 forecasts by 2% and 3% respectively. The target price is raised to NZ$43.20 from NZ$41.60.

FORECAST
Jarden forecasts a full year FY26 dividend of 113.00 cents and EPS of 161.00 cents.
Access Extra Coverage Research History >

EBO STOCK CHART

FNArena News on EBO

1
FNArena Corporate Results Monitor – 28-08-2025

Aug 28 2025 - Australia
2
Australian Broker Call *Extra* Edition – Jul 24, 2025

Jul 24 2025 - Daily Market Reports
3
Australian Broker Call *Extra* Edition – Jul 21, 2025

Jul 21 2025 - Daily Market Reports
4
In Brief: Sigma, Domino’s, Clarity & SiteMinder

Jun 20 2025 - Weekly Reports
5
Next Week At A Glance – 2-6 June 2025

May 30 2025 - Weekly Reports

Latest Healthcare services News

1
Better Times Ahead For Sonic Healthcare?

Jun 20 2025 - Australia
2
The Significance Of Cosmetique’s ASX Listing

Feb 26 2025 - Small Caps
3
Building The No 3 Diagnostic Imaging Player

Jun 19 2024 - Small Caps
4
Capitol Health’s Higher Margin Outlook

Mar 13 2024 - Small Caps
5
Treasure Chest: Ramsay Health Care

Oct 26 2023 - Treasure Chest
6
Timing Seems Right For Alcidion Group

Jun 21 2023 - Small Caps
7
No Enthusiasm To Combine ACL & Healius

Mar 21 2023 - Australia
8
Dr Boreham’s Crucible: Alcidion

Dec 13 2022 - Small Caps
9
No Straight Covid-Relief For Ramsay Health Care

Nov 15 2022 - Australia
10
Dr Boreham’s Crucible: Mach7 Technologies

Nov 14 2022 - Small Caps